drugset / Trial / NCT02958410
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of lymphocyte derived malignancies.
Timeline
- Start
- 2016-10
- Primary completion
- 2019-10
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD30-CAR-transduced T cells | Cell therapy | — | — |